> top > docs > PMC:7519301 > spans > 5854-7256 > annotations

PMC:7519301 / 5854-7256 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T22 763-766 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T23 954-964 Body_part denotes nucleotide http://purl.org/sig/ont/fma/fma82740
T24 1078-1081 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T25 1130-1140 Body_part denotes nucleotide http://purl.org/sig/ont/fma/fma82740

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T54 29-37 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T55 29-33 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T56 365-373 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T57 448-457 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T58 610-618 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T59 610-614 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T60 910-918 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T61 910-914 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T62 1026-1034 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T63 1026-1030 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T64 1381-1389 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T65 1381-1385 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T64 11-12 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T65 43-44 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T66 203-208 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T67 767-774 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T68 795-796 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T69 980-981 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T70 1082-1089 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T71 1103-1111 http://purl.obolibrary.org/obo/CLO_0001040 denotes 1 × 10−5
T72 1218-1220 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T21 209-217 Chemical denotes antigens http://purl.obolibrary.org/obo/CHEBI_59132
T22 954-964 Chemical denotes nucleotide http://purl.obolibrary.org/obo/CHEBI_36976
T23 1130-1140 Chemical denotes nucleotide http://purl.obolibrary.org/obo/CHEBI_36976

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
143 29-39 Species denotes SARS-CoV-2 Tax:2697049
144 610-620 Species denotes SARS-CoV-2 Tax:2697049
145 776-789 Species denotes coronaviruses Tax:11118
146 910-920 Species denotes SARS-CoV-2 Tax:2697049
147 1026-1034 Species denotes SARS-CoV Tax:694009
148 1381-1391 Species denotes SARS-CoV-2 Tax:2697049
149 448-457 Species denotes influenza Tax:11309
150 299-307 Disease denotes infected MESH:D007239
151 365-373 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T39 0-123 Sentence denotes Developing a vaccine against SARS-CoV-2 is a high priority for preventing and mitigating future waves of the pandemic (14).
T40 124-320 Sentence denotes Vaccine candidates typically include an insert that corresponds to one or more virus antigens, either derived computationally or from one or multiple sequence(s) sampled from infected individuals.
T41 321-532 Sentence denotes The first viral sequence derived during the COVID-19 outbreak, Wuhan-Hu-1 (available from the Global initiative on sharing all influenza data, GISAID, accession EPI_ISL_402125), was published on January 9, 2020.
T42 533-744 Sentence denotes As many vaccine programs were initiated at that time, it is likely that this SARS-CoV-2 sequence, sampled in December 2019 in Wuhan, China, is the foundation for many vaccine candidates currently in development.
T43 745-871 Sentence denotes Compared to other RNA viruses, coronaviruses have a more complex molecular machinery resulting in higher replication fidelity.
T44 872-1156 Sentence denotes Early evolutionary rate estimates for SARS-CoV-2 were ∼1 × 10−3 substitutions per nucleotide per year (15), a rate comparable to that observed during the SARS-CoV-1 outbreak (16) and in the range for other RNA viruses (1 × 10−3 to 1 × 10−5 substitutions per nucleotide per year) (17).
T45 1157-1402 Sentence denotes While the evolutionary rate is likely to decrease over time (18), it is important to monitor the introduction of any mutation that may compromise the potential efficacy of vaccine candidates derived from the first available SARS-CoV-2 sequences.